West Coast upstart Arcus Biosciences has bagged its very own PD-1 antibody to take into the clinic with its immuno-oncology pipeline drugs.
Wuxi Biologics has confirmed its intention to go public in an IPO application that reveals the contracter has seen revenue double and profits increase three-fold since 2014.